Effect of growth hormone on ovarian dysfunction in controlled ovarian hyperstimulation
In the controlled superovulation (COH) process of in vitro fertilization-embryo transfer (IVF-ET), the effects of gonadotropin (Gn) combined with recombinant human growth hormone (GH) on the treatment of patients with ovarian dysfunction were observed and explored. METHODS: Choosing to enter the in vitro fertilization-embryo transfer-pregnancy cycle before treatment showed that there was an ovarian dysfunction and received IVF/ICSI at the Reproductive Medicine Research Center of the First Affiliated Hospital of Guangxi Medical University from the beginning of March 2010 to the end of November 2011. Eighty patients were randomly divided into two groups: 40 patients with gonadotropin combined with GH were in the study group (GH group), and 40 patients with gonadotropin alone and no GH were used as the control group. Compare the total amount and days of gonadotropin use, the amount of GnRH-a, the level of human gonadotropin (HCG) and the endometrial thickness, the number of eggs and the number of mature oocytes, fertilization rate. , cleavage rate, number of embryos obtained, number of high quality embryos, embryo implantation rate and pregnancy rate, serum levels of insulin-like growth factor-1 (IGF-1) and insulin-like growth factor binding protein were detected by ELISA. The concentration of 3 (IGFBP-3) was compared for the difference. Results: 1. The gonadotropin medication days and doses in the study group were compared with the control group, P>0.05, the difference was not statistically significant; the GnRH-a Dafillin dosage was P>0.05, the difference was not statistically significant.
Zomacton Growth hormone IVF-ET Ovarian poor responder COH IGF-1 IGFBP-3